These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 18765531)

  • 1. Oncostatin M induces bone loss and sensitizes rat osteosarcoma to the antitumor effect of Midostaurin in vivo.
    Brounais B; Chipoy C; Mori K; Charrier C; Battaglia S; Pilet P; Richards CD; Heymann D; Rédini F; Blanchard F
    Clin Cancer Res; 2008 Sep; 14(17):5400-9. PubMed ID: 18765531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of osteoblast markers and induction of the glial fibrillary acidic protein by oncostatin M in osteosarcoma cells require PKCdelta and STAT3.
    Chipoy C; Berreur M; Couillaud S; Pradal G; Vallette F; Colombeix C; Rédini F; Heymann D; Blanchard F
    J Bone Miner Res; 2004 Nov; 19(11):1850-61. PubMed ID: 15476586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long term oncostatin M treatment induces an osteocyte-like differentiation on osteosarcoma and calvaria cells.
    Brounais B; David E; Chipoy C; Trichet V; Ferré V; Charrier C; Duplomb L; Berreur M; Rédini F; Heymann D; Blanchard F
    Bone; 2009 May; 44(5):830-9. PubMed ID: 19168167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitization of osteosarcoma cells to apoptosis by oncostatin M depends on STAT5 and p53.
    Chipoy C; Brounais B; Trichet V; Battaglia S; Berreur M; Oliver L; Juin P; Rédini F; Heymann D; Blanchard F
    Oncogene; 2007 Oct; 26(46):6653-64. PubMed ID: 17471233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct anti-cancer effect of oncostatin M on chondrosarcoma.
    David E; Guihard P; Brounais B; Riet A; Charrier C; Battaglia S; Gouin F; Ponsolle S; Bot RL; Richards CD; Heymann D; Rédini F; Blanchard F
    Int J Cancer; 2011 Apr; 128(8):1822-35. PubMed ID: 21344373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncostatin-M: a new bone active cytokine that activates osteoblasts and inhibits bone resorption.
    Jay PR; Centrella M; Lorenzo J; Bruce AG; Horowitz MC
    Endocrinology; 1996 Apr; 137(4):1151-8. PubMed ID: 8625883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma.
    Heymann D; Ory B; Blanchard F; Heymann MF; Coipeau P; Charrier C; Couillaud S; Thiery JP; Gouin F; Redini F
    Bone; 2005 Jul; 37(1):74-86. PubMed ID: 15894525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncostatin M is a growth factor for Ewing sarcoma.
    David E; Tirode F; Baud'huin M; Guihard P; Laud K; Delattre O; Heymann MF; Heymann D; Redini F; Blanchard F
    Am J Pathol; 2012 Nov; 181(5):1782-95. PubMed ID: 22982441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncostatin M induces IL-33 expression in liver endothelial cells in mice and expands ST2+CD4+ lymphocytes.
    Arshad MI; Guihard P; Danger Y; Noel G; Le Seyec J; Boutet MA; Richards CD; L'Helgoualc'h A; Genet V; Lucas-Clerc C; Gascan H; Blanchard F; Piquet-Pellorce C; Samson M
    Am J Physiol Gastrointest Liver Physiol; 2015 Oct; 309(7):G542-53. PubMed ID: 26251474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel function of Oncostatin M as a potent tumour-promoting agent in lung.
    Lauber S; Wong S; Cutz JC; Tanaka M; Barra N; Lhoták S; Ashkar A; Richards CD
    Int J Cancer; 2015 Feb; 136(4):831-43. PubMed ID: 24976180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncostatin m, an inflammatory cytokine produced by macrophages, supports intramembranous bone healing in a mouse model of tibia injury.
    Guihard P; Boutet MA; Brounais-Le Royer B; Gamblin AL; Amiaud J; Renaud A; Berreur M; Rédini F; Heymann D; Layrolle P; Blanchard F
    Am J Pathol; 2015 Mar; 185(3):765-75. PubMed ID: 25559270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relevance of a new rat model of osteoblastic metastases from prostate carcinoma for preclinical studies using zoledronic acid.
    Lamoureux F; Ory B; Battaglia S; Pilet P; Heymann MF; Gouin F; Duteille F; Heymann D; Redini F
    Int J Cancer; 2008 Feb; 122(4):751-60. PubMed ID: 17960623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncostatin M in combination with tumor necrosis factor alpha induces cartilage damage and matrix metalloproteinase expression in vitro and in vivo.
    Hui W; Rowan AD; Richards CD; Cawston TE
    Arthritis Rheum; 2003 Dec; 48(12):3404-18. PubMed ID: 14673992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncostatin M induces cell detachment and enhances the metastatic capacity of T-47D human breast carcinoma cells.
    Jorcyk CL; Holzer RG; Ryan RE
    Cytokine; 2006 Mar; 33(6):323-36. PubMed ID: 16713283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor necrosis factor therapy inhibits lung metastasis in an osteosarcoma cell line.
    Kato H; Wakabayashi H; Naito Y; Kato S; Nakagawa T; Matsumine A; Sudo A
    Oncology; 2015; 88(3):139-46. PubMed ID: 25402182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin D fails to prevent serum starvation- or staurosporine-induced apoptosis in human and rat osteosarcoma-derived cell lines.
    Witasp E; Gustafsson AC; Cotgreave I; Lind M; Fadeel B
    Biochem Biophys Res Commun; 2005 May; 330(3):891-7. PubMed ID: 15809080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of oncostatin-M on proliferation and activity in osteoblastic MC3T3-E1 cells.
    Shih C; Yen CC
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Oct; 62(10):710-6. PubMed ID: 10533301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncostatin-M enhances osteoinduction in a rabbit critical calvarial defect model.
    Moxham JP
    Laryngoscope; 2007 Oct; 117(10):1790-7. PubMed ID: 17713450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of low-dose tumor necrosis factor-alpha in combination with STEALTH liposomal cisplatin (SPI-077) on soft-tissue- and osteosarcoma-bearing rats.
    Hoving S; van Tiel ST; Eggermont AM; ten Hagen TL
    Anticancer Res; 2005; 25(2A):743-50. PubMed ID: 15868905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced in-vitro and in-vivo suppression of A375 melanoma by combined IL-24/OSM adenoviral-mediated gene therapy.
    Xu Y; Zhang F; Qin L; Miao J; Sheng W; Xie Y; Xu X; Yang J; Qian H
    Melanoma Res; 2014 Feb; 24(1):20-31. PubMed ID: 24300090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.